Iterum Therapeutics plc (NASDAQ:ITRM) Short Interest Update

Iterum Therapeutics plc (NASDAQ:ITRM) was the recipient of a large decline in short interest in the month of August. As of August 15th, there was short interest totalling 443,600 shares, a decline of 80.5% from the July 31st total of 2,270,000 shares. Based on an average trading volume of 236,600 shares, the short-interest ratio is currently 1.9 days. Approximately 2.1% of the shares of the company are sold short.

Wall Street Analyst Weigh In

Separately, HC Wainwright lowered their price objective on Iterum Therapeutics from $6.00 to $5.00 and set a “buy” rating on the stock in a report on Thursday, August 15th.

Iterum Therapeutics Stock Down 4.3 %

Shares of NASDAQ ITRM traded down $0.05 during midday trading on Tuesday, hitting $1.12. The company had a trading volume of 237,122 shares, compared to its average volume of 354,384. Iterum Therapeutics has a twelve month low of $0.62 and a twelve month high of $2.50. The firm has a market capitalization of $18.54 million, a price-to-earnings ratio of -0.42 and a beta of 2.26. The business has a 50-day simple moving average of $1.23 and a two-hundred day simple moving average of $1.39.

Iterum Therapeutics Company Profile

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.